CA3029004A1 - Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer - Google Patents

Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer Download PDF

Info

Publication number
CA3029004A1
CA3029004A1 CA3029004A CA3029004A CA3029004A1 CA 3029004 A1 CA3029004 A1 CA 3029004A1 CA 3029004 A CA3029004 A CA 3029004A CA 3029004 A CA3029004 A CA 3029004A CA 3029004 A1 CA3029004 A1 CA 3029004A1
Authority
CA
Canada
Prior art keywords
exemplary embodiment
compound
unsubstituted
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3029004A
Other languages
English (en)
French (fr)
Other versions
CA3029004C (en
Inventor
Tsze TSANG
Csaba J. Peto
David M. Jablons
Hassan Lemjabbar-Alaoui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlasmedx Inc
University of California San Diego UCSD
Original Assignee
Atlasmedx Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlasmedx Inc, University of California San Diego UCSD filed Critical Atlasmedx Inc
Publication of CA3029004A1 publication Critical patent/CA3029004A1/en
Application granted granted Critical
Publication of CA3029004C publication Critical patent/CA3029004C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3029004A 2016-06-24 2017-06-23 Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer Active CA3029004C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662354449P 2016-06-24 2016-06-24
US62/354,449 2016-06-24
US201662426095P 2016-11-23 2016-11-23
US62/426,095 2016-11-23
PCT/US2017/039119 WO2017223516A1 (en) 2016-06-24 2017-06-23 Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA3029004A1 true CA3029004A1 (en) 2017-12-28
CA3029004C CA3029004C (en) 2025-09-09

Family

ID=

Also Published As

Publication number Publication date
MX2018015893A (es) 2019-08-01
ES2964531T3 (es) 2024-04-08
SG11201811393WA (en) 2019-01-30
US20190337928A1 (en) 2019-11-07
KR102494294B1 (ko) 2023-01-31
CN109843874A (zh) 2019-06-04
BR112018076821A2 (pt) 2019-04-02
IL263917A (en) 2019-02-28
AU2017280334A1 (en) 2019-01-17
JP2019522681A (ja) 2019-08-15
ZA202301066B (en) 2024-05-30
PL3475272T3 (pl) 2024-04-29
US20190352283A1 (en) 2019-11-21
KR20190033534A (ko) 2019-03-29
US11072600B2 (en) 2021-07-27
IL263917B (en) 2022-07-01
US10640493B2 (en) 2020-05-05
EP3475272B1 (en) 2023-09-13
US20220402894A1 (en) 2022-12-22
HUE066216T2 (hu) 2024-07-28
JP2022037004A (ja) 2022-03-08
US12145925B2 (en) 2024-11-19
CN109843874B (zh) 2022-05-27
AU2017280334C1 (en) 2022-10-20
AU2017280334B2 (en) 2021-07-29
MX2021013641A (es) 2022-01-06
EP3475272A1 (en) 2019-05-01
WO2017223516A1 (en) 2017-12-28
MX387726B (es) 2025-03-18
PT3475272T (pt) 2023-12-15
ZA201808562B (en) 2023-12-20
JP7033588B2 (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
US12145925B2 (en) Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
CA2759241C (en) Novel anti-inflammatory agents
US10202360B2 (en) Therapeutic compounds
WO2016131381A1 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
WO2006024837A1 (en) Isoindolin-1-one derivatives
CN118005656A (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
KR20170035944A (ko) PI3K, mTOR 저해제로서 융합된 퀴놀린 화합물
TW580498B (en) A novel amide compound and a pharmaceutical composition containing the same
US11708352B2 (en) Anti-cancer compounds
CA3135921C (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
AU2008252628A1 (en) Bicyclosulfonyl acid (BCSA) compounds and their use as therapeutic agents
KR20190125367A (ko) 아제티딘 유도체
CA3029004C (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
HK40002445A (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
CN111630048B (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
BR112018076821B1 (pt) Compostos ou sal, hidrato ou solvato dos mesmos, seus usos, formulação farmacêutica e método in vitro de inibição de parp1 e/ou parp2 e/ou tubulina
WO2025215187A1 (en) Therapeutic compounds and their use
WO2025240834A1 (en) Nsd2-targeted chemical degraders and compositions and methods of use thereof
WO2025242880A1 (en) Therapeutic compounds and their use
CN103052641B (zh) 作为c‑Met抑制剂的新型稠环杂环衍生物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220623

EEER Examination request

Effective date: 20220623

EEER Examination request

Effective date: 20220623

EEER Examination request

Effective date: 20220623

EEER Examination request

Effective date: 20220623